Neurosense to Evaluate Biological Changes in People with Neurodegenerative Disease

New York, April 10, 2024 - PRISM MarketView - NeuroSense Therapeutics (Nasdaq: NRSN) has announced it will collaborate with Lonza (SIX: LONN), a global development and manufacturing partner to the pharma, biotech and nutrition industries, to evaluate biological changes occurring in people with neurodegenerative diseases.

This agreement will allow NeuroSense to leverage its extensive experience in biomarker utilization in neurodegenerative diseases, while Lonza provides development, optimization, and qualification of a method measuring biomarkers from NDEs, which will be integrated into the development of NeuroSense’s lead product candidate for ALS, PrimeC.

NDEs are small extracellular vesicles generated by neurons that encapsulate a variety of molecules such as proteins, nucleic acids, and metabolites. NDEs can pass the blood-brain barrier and noninvasively provide a depiction of the current physiological status of neurons in the brain. 

Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis.

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense’s strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.

PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.

PRISM MarketView
info@prismmarketview.com
646-863-6341